Heeschen, C.

patient level troponin serum cd 40 ligand abciximab event infarction troponin t angina study follow-up syndrome treatment value death placebo -10 month circulation ligand percent factor marker group protein outcome growth baseline 6 months trial c-reactive protein nonfatal disease figure 6- month follow-up lesion benefit chest pain heart c-reactive plgf levels analysis hazard ratio troponin t levels mpo serum levels thrombu 30 days heeschen artery disease hazard ratio quartile il -10 model platelet scd 40l randomization event rates characteristic quintile thrombus formation hgf serum levels hgf levels liter prognostic placental growth factor glycoprotein result elevation prognostic value activation vegf serum levels milliliter effect threshold chest 72 hours table vegf levels